Fetal Abnormalities of Metabolic Origin by Mamunes, Peter
Fetal Abnormalities of Metabolic Origin* 
PETER MAMUNES, M.D. 
Associate Professor of Pediatrics, 
Medical College of Virginia, Richmond, Virginia 
The subject of my discussion is prenatal diag-
nosis of genetic disorders of a metabolic rather 
than a chromosomal nature. Whereas the chromo-
somal defects are the result of either the transmis-
sion of a translocated chromosome from a single 
parent to its offspring or an error in meiosis or 
mitosis, almost all metabolic disorders are inherited 
in an autosomal recessive fashion. Therefore, ex-
cept in rare instances, the only clue to the possible 
presence of an inborn error of metabolism (IEM) 
in the fetus is that a previous child of the parents 
has had the disorder. This history identifies both 
mother and father as heterozygotes for the delete-
rious gene and thus forewarns that each subsequent 
pregnancy is at a 1 : 4 risk of yielding the disorder 
again. By studying the amniotic fluid of the at-risk 
fetus, it is now possible to determine if the disorder 
is present, and if so, to prevent its occurrence by 
therapeutic abortion. My main purpose is first to 
review the status of the art of amniocentesis and 
biochemical analysis of the material thus obtained, 
and then to examine the impact this procedure will 
have on the incidence and management of the 
IEM. 
Amniocentesis in the second half of pregnancy 
for the diagnosis and treatment of erythroblastosis 
has been widely used for almost two decades with a 
minimum of morbidity or mortality to the mother 
or fetus . Theoretical risks of the procedure (fetal 
abortion, puncture, or induced malformation, and 
maternal bleeding, infection, or sensitization) had 
not been reported when the accumulated experience 
of 500 amniocenteses during the first half of preg-
nancy were reviewed one year ago (Nadler: BD, 
1971). Prior to the 10th week of gestation there are 
less than 30 cc. of amniotic fluid present, and the 
uterus has not yet risen outside of the pelvis. Be-
cause of these facts, a transabdominal approach at 
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this time is usually unsuccessful and the transvaginal 
route is attendant with a high risk of complications 
(especially abortion) (Fuchs, 1971). For these rea-
sons the procedure is usually withheld until the 
13th to 14th week, at which time approximately 
100-120 cc. of amniotic fluid are present, and the 
uterus can easily be positioned to the anterior mid-
line by bimanual examinations. Most investigators 
do not use placental localization, and they accom-
plish the procedure on an out-patient basis. In the 
combined experience of four investigators only 
11 % of 353 taps had to be repeated in order to get 
adequate material; initial failure in the majority of 
cases was due to contamination by gross blood 
(Nadler: BD, 1971). 
Almost all of the cells present in the amniotic 
fluid are of fetal origin (either from amnion or 
skin), and some are viable. If the removed fluid is 
placed in a siliconized container, the cells will not 
adhere to the walls, and they can be shipped by 
mail over a 48-hour period or stored overnight in a 
refrigerator. When these cells are isolated from the 
amniotic fluid by centrifugation and placed in 
appropriate tissue culture media, their growth and 
multiplication rapidly ensues. After. two subcultures 
and a total of four weeks of growth, hopefully a 
sufficient number of cells is present for analysis . 
Depending upon the disorder, the biochemical test 
performed is the measurement of either specific 
enzyme activity or of possible accumulation of a 
substance (such as mucopolysaccharides). Unfortu-
nately, tissue sufficient in quantity to perform the 
desired test can be obtained only 75-90% of the 
time (Nadler: SM!, 1971); with chromosomal 
studies, success rates of 95-99% have been 
achieved (Nadler: BD, 1971; SM!, 1971). 
The major premise utilized with this procedure 
is that these cultured amniotic cells accurately re-
flect the specific characteristics of the disorder in 
question. Previous studies of skin fibroblast cultures 
have proven that these cells do reflect the deficient 
state of the whole organism in most disorders. 
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When the amniotic fluid cells are first removed 
they have the morphological appearance of epi-
thelial cells, but in culture they take on the bio-
chemical and morphological characteristics of fibro-
blasts. However, many factors affecting the enzyme 
activity of these cells must be considered before 
proper interpretation of results is possible (for 
example, stage of gestation, stage of growth of cells, 
degree of cell confluency). If one also remembers 
that these techniques must be refined to the point 
where the investigator can accurately differentiate 
the heterozygote from the homozygote, then hope-
fully he is left with the highest regard for the 
complexities of this diagnostic procedure. 
In addition to the use of cultured amniotic 
fluid cells, biochemical analysis of uncultured am-
niotic fluid cells or of the amniotic fluid itself may 
provide sufficient information to make an accurate 
prenatal diagnosis. Although presently less than a 
half-dozen disorders can be detected by these 
methods (Nadler: BD, 1971), we hope further re-
finements will serve to increase this number, be-
cause such progress would obviate the minimum 
4-week delay required to culture. Using cultured 
cells to establish the diagnosis leaves only a pre-
cious week or two to effect any needed abortion, 
as there are substantial medical, if not legal, re-
strictions to performing a therapeutic abortion 
much after the 20th gestational week. 
Now that we have briefly described the capa-
bilities and limitations of the procedure itself, let 
us examine how its usage can affect our present 
management of the IEM. The various modalites 
of treatment presently utilized (for example, limiting 
substrate, providing deficient end product), for the 
most part, do not attack the basic problem-that 
of decreased enzyme activity. Recently, there has 
been much discussion regarding the feasibility of 
gene therapy, that is, the isolation of some of the 
patient's somatic cells, the alteration of their genetic 
endowment in vitro, and their replacement in the 
individual. Other possible methods of providing the 
deficient enzyme include organ transplantation or 
specific enzyme replacement, but none of these ap-
proaches (particularly gene therapy) appears fea-
sible in the next few years. 
The only preventive measures available in the 
past were genetic counseling and abortion of male 
fetuses of mothers carrying a serious sex-linked 
disease such as muscular dystrophy (the sex of the 
fetus can be fairly accurately established by a study 
of the sex chromatin status of uncultured or cul-
tured amniotic fluid cells). Genetic counseling is a 
good preventive measure because the majority of 
parents given a 1 : 4 recurrence risk will be de-
terred from future pregnancies, especially where 
the disorder is lethal or uncontrollable and where 
there are already one or more normal children in 
the family. But what of the parents whose first 
child has a serious inborn error of metabolism and 
who wish a normal child but are rightfully fearful 
of the 1 :4 recurrence risk? This is where the am-
niocentesis and subsequent determination of the 
specific enzyme content of fetal cells is especially 
useful. I presently have two sets of young parents, 
each with an infant with Hurler's syndrome, who 
wish to have their first normal child. Only 3-4 
laboratories in the country have developed the nec-
essary techniques for the in utero diagnosis of this 
condition. Should one of these laboratories agree 
to monitor the pregnancy, and if the parents con-
sent to an abortion if studies show an involved 
fetus, either the amniotic fluid (with the cells) or 
already cultured cells would be mailed to that la-
boratory. 
At the present time there are less than twelve 
laboratories active in the prenatal diagnosis of the 
IEM-most, if not all, of these operate in a re-
search rather than service capacity. A coordination 
of these various centers is needed because no one 
laboratory can perform all the available tests. As 
of one year ago there had been less than 25 ther-
apeutic abortions performed in the United States 
for proven fetal metabolic disorders (Nadler: BD, 
1971). This number would have been much higher 
had the biochemical determinations been more 
readily available. 
What effect will this development have in re-
ducing the actual number of infants born with 
metabolic disorders? One should remember that at 
present we must have an index case before know-
ing that we should monitor future pregnancies. 
Therefore, the birth of a majority of patients with 
IEM will not be prevented. Making the assump-
tion that the goal of a family is to have two normal 
children, Motulsky has calculated that performing 
therapeutic abortions on all fetuses found to have a 
metabolic disorder (after one sibling involvement) 
will only reduce the incidence of that disorder by 
12.5-34% (Motulsky, 1971). 
In order to substantially reduce the incidence 
of these disorders we would need to identify which 
parent pairs are heterozygotic for the same delete-
rious gene before the delivery of their first affected 
child. It would be impractical to screen all pros-
pective parents for heterozygosity for most of the 
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over 150 autosomal recessive IEM, because either 
the disease is so rare, or the test is too difficult to 
perform on a mass basis. However, it is presently 
feasible to screen certain high-risk groups for cer-
tain disorders-for instance, sickle trait testing for 
Blacks and the measurement of serum hexosamin-
idase A (for Gaucher's disease) in Ashkenazi Jews. 
Also, because of its prevalence in Caucasians, mass 
screening for the gene for cystic fibrosis should be 
performed once a simple reliable test is developed. 
Many ethical, moral, legal, and theological 
issues are raised with our ability to define the 
metabolic status of the fetus. Time does not permit 
any in-depth discussion of these matters, but Jet me 
pose two questions as examples: 
1. Should one abort a fetus who has galacto-
semia, pyridoxine-responsive homocysti-
nuria, or phenylketonuria? These disorders 
are severe if untreated but the prognosis is 
good with dietary restriction or vitamin 
supplementation. 
2. Should one induce an abortion where only 
one of nonidentical twins has an untreat-
able metabolic disorder? 
At present it is felt that the final decision must be 
left to the parents, with the obstetrician and genet-
icist providing informed but impartial counsel. Per-
haps shortly, each center involved in prenatal diag-
nosis will establish a board of physicians ,and lay 
people to reach a consensus i11 each given case. 
In summary; it is now theoretically possible to 
diagnose approximately 40 different inbor,n errors 
of inetabolism in a fetus early enough in gestation 
to perform a therapeutic abortion. However, most 
of these disorders are extremely rare, the tech-
niques laboriOus, and diagnosis possible ~nly . after 
one sibling is already involved. For now, higher 
priority should be given to the development of 
procedures for massive heterozygote screening and 
iptrauterine diagnosis .of more common recessive 
diseases such as cystic fibrosis and sickle cell anemia. 
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